S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   163.71 (-0.70%)
MSFT   278.58 (-0.62%)
META   169.11 (-0.67%)
GOOGL   116.54 (-0.65%)
AMZN   138.22 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.99 (-2.78%)
NIO   20.15 (-0.10%)
BABA   91.03 (+0.21%)
AMD   97.97 (-2.10%)
MU   58.68 (-4.51%)
T   18.03 (+0.17%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.68 (-0.63%)
DIS   109.65 (+0.49%)
AMC   24.01 (+0.21%)
PYPL   95.58 (-0.71%)
PFE   49.50 (-0.14%)
NFLX   231.89 (-0.69%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   163.71 (-0.70%)
MSFT   278.58 (-0.62%)
META   169.11 (-0.67%)
GOOGL   116.54 (-0.65%)
AMZN   138.22 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.99 (-2.78%)
NIO   20.15 (-0.10%)
BABA   91.03 (+0.21%)
AMD   97.97 (-2.10%)
MU   58.68 (-4.51%)
T   18.03 (+0.17%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.68 (-0.63%)
DIS   109.65 (+0.49%)
AMC   24.01 (+0.21%)
PYPL   95.58 (-0.71%)
PFE   49.50 (-0.14%)
NFLX   231.89 (-0.69%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   163.71 (-0.70%)
MSFT   278.58 (-0.62%)
META   169.11 (-0.67%)
GOOGL   116.54 (-0.65%)
AMZN   138.22 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.99 (-2.78%)
NIO   20.15 (-0.10%)
BABA   91.03 (+0.21%)
AMD   97.97 (-2.10%)
MU   58.68 (-4.51%)
T   18.03 (+0.17%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.68 (-0.63%)
DIS   109.65 (+0.49%)
AMC   24.01 (+0.21%)
PYPL   95.58 (-0.71%)
PFE   49.50 (-0.14%)
NFLX   231.89 (-0.69%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   163.71 (-0.70%)
MSFT   278.58 (-0.62%)
META   169.11 (-0.67%)
GOOGL   116.54 (-0.65%)
AMZN   138.22 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.99 (-2.78%)
NIO   20.15 (-0.10%)
BABA   91.03 (+0.21%)
AMD   97.97 (-2.10%)
MU   58.68 (-4.51%)
T   18.03 (+0.17%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.68 (-0.63%)
DIS   109.65 (+0.49%)
AMC   24.01 (+0.21%)
PYPL   95.58 (-0.71%)
PFE   49.50 (-0.14%)
NFLX   231.89 (-0.69%)
Followed 228 Times  
NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$49.50
-0.07 (-0.14%)
(As of 08/9/2022 09:21 AM ET)
Add
Compare
Today's Range
$49.39
▼
$49.50
50-Day Range
$46.53
▼
$53.96
52-Week Range
$40.94
▼
$61.71
Volume
100 shs
Average Volume
17.13 million shs
Market Capitalization
$277.74 billion
P/E Ratio
9.69
Dividend Yield
3.25%
Price Target
$57.50

Pfizer MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.0% Upside
$57.50 Price Target
Short Interest
Healthy
1.20% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.67
Upright™ Environmental Score
News Sentiment
0.02mentions of Pfizer in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$2.08 M Sold Last Quarter
Proj. Earnings Growth
-17.58%
From $6.54 to $5.39 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

49th out of 1,098 stocks

Pharmaceutical Preparations Industry

14th out of 536 stocks

See Top Rated MarketRank™ Stocks Here
PFE stock logo

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Price Performance

PFE Stock opened at $49.57 on Tuesday. The stock has a 50-day moving average price of $51.00 and a two-hundred day moving average price of $51.04. The stock has a market cap of $278.13 billion, a PE ratio of 9.70, a price-to-earnings-growth ratio of 0.60 and a beta of 0.67. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. Pfizer has a 1 year low of $40.94 and a 1 year high of $61.71.

Pfizer (NYSE:PFE - Get Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The firm had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. During the same quarter in the prior year, the company earned $1.07 EPS. The company's revenue was up 46.8% on a year-over-year basis. Equities analysts forecast that Pfizer will post 6.54 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.23%. Pfizer's dividend payout ratio is 31.31%.

Analyst Ratings Changes

Several research analysts have issued reports on PFE shares. Wells Fargo & Company reduced their price objective on Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. SVB Leerink reduced their price objective on Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a report on Friday, July 29th. Barclays upped their price objective on Pfizer from $50.00 to $52.00 and gave the stock an "equal weight" rating in a report on Monday, August 1st. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research report on Tuesday, June 28th. Finally, Berenberg Bank set a $50.00 target price on shares of Pfizer in a research report on Friday, May 27th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Insider Transactions at Pfizer

In related news, SVP Jennifer B. Damico sold 4,000 shares of the firm's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now directly owns 10,846 shares of the company's stock, valued at approximately $585,250.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at $760,732. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock worth $2,075,003 in the last three months. Insiders own 0.05% of the company's stock.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

August 3, 2022 | marketbeat.com
3 Pharma Stocks' Post-Earnings Price Moves (PFE)
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
August 2, 2022 | marketbeat.com
3 Health Care Stocks in Great Financial Health (PFE)
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.
August 9, 2022 | Investing Trends (Ad)
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
July 18, 2022 | marketbeat.com
Is it Time to Cash Out Novavax Stock? (PFE)
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.
July 18, 2022 | marketbeat.com
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.
August 9, 2022 | washingtonpost.com
Pfizer and Valneva developing new Lyme disease vaccine - The Washington Post
August 8, 2022 | ft.com
BioNTech and Pfizer to begin clinical trial of vaccine for new Covid variants - Financial Times
August 8, 2022 | finance.yahoo.com
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
August 9, 2022 | Investing Trends (Ad)
Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
August 8, 2022 | marketwatch.com
Pfizer strikes $5.4 billion deal for Global Blood Therapeutics
August 8, 2022 | seekingalpha.com
Valneva Stock: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love (NASDAQ:VALN) - Seeking Alpha
August 5, 2022 | seekingalpha.com
Pfizer Looks Oversold (NYSE:PFE) - Seeking Alpha
August 5, 2022 | bloomberg.com
Pfizer in Talks to Buy Sickle-Cell Drugmaker for $5 Billion, WSJ Reports - Bloomberg
August 5, 2022 | fool.com
Better Dividend Stock: Chevron or Pfizer? - The Motley Fool
August 3, 2022 | fool.com
1 Reason to Buy Pfizer Stock After Earnings, and 1 Reason to Sell
August 3, 2022 | businesswire.com
Model N and Pfizer Innovate Drug Price Transparency Reporting - Business Wire
August 3, 2022 | businesswire.com
Amber Specialty Pharmacy Added to Pfizer's Limited Distribution Network for Oncology Portfolio - Business Wire
August 3, 2022 | fool.com
1 Reason to Buy Pfizer Stock After Earnings, and 1 Reason to Sell - The Motley Fool
August 3, 2022 | fool.com
What 1 Key COVID Drug's News Might Mean For Pfizer - The Motley Fool
August 3, 2022 | americanbankingnews.com
Pfizer (NYSE:PFE) Given New $52.00 Price Target at Barclays
August 2, 2022 | bloomberg.com
Should I Get a Covid Vaccine Booster? Fourth Pfizer Dose Slashes Risk of Omicron - Bloomberg
August 2, 2022 | barrons.com
Pfizer, Cisco, and 5 Other Stocks With the Cash Flow to Raise Their Dividends - Barron's
August 2, 2022 | americanbankingnews.com
The Goldman Sachs Group Analysts Give Pfizer (NYSE:PFE) a $50.00 Price Target
August 1, 2022 | americanbankingnews.com
Pfizer (NYSE:PFE) Given New $53.00 Price Target at SVB Leerink
July 31, 2022 | marketwatch.com
: Moderna and Pfizer to start clinical trials for COVID-19 boosters that target BA.5 ‘in the near future’
July 31, 2022 | nasdaq.com
Pfizer Inc. (NYSE:PFE) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts - Nasdaq
July 30, 2022 | barrons.com
Pfizer's Updated Covid-19 Booster Will 'Likely' Be Ready in Early Fall, CEO Says - Barron's
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 6/10 Dividend
5/12/2022
Dividend Payable
6/10/2022
Last Earnings
7/28/2022
Ex-Dividend for 9/6 Dividend
7/28/2022
Today
8/09/2022
Dividend Payable
9/06/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:PFE
CUSIP
71708110
CIK
78003
Web
www.pfizer.com
Phone
(212) 733-2323
Fax
302-655-5049
Employees
79,000
Year Founded
1849

Price Target and Rating

Average Stock Price Forecast
$57.50
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+16.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
18 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.11
Trailing P/E Ratio
9.69
Forward P/E Ratio
7.57
P/E Growth
0.6
Net Income
$21.98 billion
Net Margins
28.92%
Pretax Margin
32.08%
Return on Equity
44.38%
Return on Assets
19.24%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
1.39
Quick Ratio
1.13

Sales & Book Value

Annual Sales
$81.29 billion
Price / Sales
3.42
Cash Flow
$5.45 per share
Price / Cash Flow
9.09
Book Value
$13.80 per share
Price / Book
3.59

Miscellaneous

Outstanding Shares
5,610,900,000
Free Float
5,608,091,000
Market Cap
$277.74 billion
Optionable
Optionable
Beta
0.67

Social Links


Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PFE shares.
View PFE analyst ratings or view top-rated stocks.

What is Pfizer's stock price forecast for 2022?

18 analysts have issued twelve-month price targets for Pfizer's stock. Their PFE share price forecasts range from $45.00 to $76.00. On average, they expect the company's stock price to reach $57.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for PFE or view top-rated stocks among Wall Street analysts.

How has Pfizer's stock performed in 2022?

Pfizer's stock was trading at $59.05 on January 1st, 2022. Since then, PFE shares have decreased by 16.1% and is now trading at $49.57.
View the best growth stocks for 2022 here.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PFE earnings forecast.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Thursday, July, 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. The biopharmaceutical company earned $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a trailing twelve-month return on equity of 44.38% and a net margin of 28.92%. The company's quarterly revenue was up 46.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.07 EPS.
Read the conference call transcript.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, June 23rd. Investors of record on Wednesday, June 29th will be paid a dividend of $0.40 per share on Tuesday, September 6th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date of this dividend is Thursday, July 28th.
Read our dividend analysis for PFE.

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 3.25%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 29.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $6.30-$6.45 for the period, compared to the consensus earnings per share estimate of $6.62. The company issued revenue guidance of $98.00 billion-$102.00 billion, compared to the consensus revenue estimate of $102.92 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.33%), TD Asset Management Inc. (0.17%), DekaBank Deutsche Girozentrale (0.15%), Robeco Institutional Asset Management B.V. (0.14%), Los Angeles Capital Management LLC (0.13%) and Baird Financial Group Inc. (0.12%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock, Scott Gottlieb and William R Carapezzi Jr.
View institutional ownership trends.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $49.57.

How much money does Pfizer make?

Pfizer (NYSE:PFE) has a market capitalization of $278.13 billion and generates $81.29 billion in revenue each year. The biopharmaceutical company earns $21.98 billion in net income (profit) each year or $5.11 on an earnings per share basis.

How many employees does Pfizer have?

Pfizer employs 79,000 workers across the globe.

Does Pfizer have any subsidiaries?

The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Holdings B.V., AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alacer, Alpharma Holdings LLC, Alpharma Pharmaceuticals LLC, Alpharma Specialty Pharma LLC, Alpharma USHP LLC, American Food Industries LLC, Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Array BioPharma, Ayerst-Wyeth Pharmaceuticals LLC, BIND Therapeutics Inc., BINESA 2002 S.L., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Bioren LLC, Blue Whale Re Ltd., C.E. Commercial Holdings C.V., C.E. Commercial Investments C.V., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Continental Pharma Inc., Covx, Covx Technologies Ireland Limited, Cyanamid Inter-American Corporation, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion LUV Development Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Excaliard Pharmaceuticals Inc., Farminova Produtos Farmaceuticos de Inovacao Lda., Farmogene Productos Farmaceuticos Lda, Ferrosan A/S, Ferrosan International A/S, Ferrosan S.R.L., FoldRx Pharmaceuticals Inc., Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, G. D. Searle LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Greenstone LLC, Haptogen Limited, Hospira, Hospira (China) Enterprise Management Co. Ltd., Hospira Adelaide Pty Ltd, Hospira Aseptic Services Limited, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Chile Limitada, Hospira Deutschland GmbH, Hospira Enterprises B.V., Hospira France SAS, Hospira Healthcare B.V., Hospira Healthcare Corporation, Hospira Healthcare India Private Limited, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Invicta S.A., Hospira Ireland Holdings Unlimited Company, Hospira Ireland Sales Limited, Hospira Japan G.K., Hospira Limited, Hospira Malaysia Sdn Bhd, Hospira NZ Limited, Hospira Nordic AB, Hospira Philippines Inc., Hospira Portugal LDA, Hospira Produtos Hospitalares Ltda., Hospira Pte. Ltd., Hospira Pty Limited, Hospira Puerto Rico LLC, Hospira Singapore Pte Ltd, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, Industrial Santa Agape S.A., InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, JMI-Daniels Pharmaceuticals Inc., John Wyeth & Brother Limited, Kiinteistö oy Espoon Pellavaniementie 14, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Korea Pharma Holding Company Limited, Laboratoires Pfizer S.A., Laboratorios Parke Davis S.L., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Meridian Medical Technologies Inc., Meridian Medical Technologies Limited, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, NextWave Pharmaceuticals Incorporated, P-D Co. LLC, PAH USA IN8 LLC, PF Americas Holding C.V., PF Asia Manufacturing B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings S.a.r.l., PF Prism S.á.r.l., PFE Holdings G.K., PFE PHAC Holdings 1 LLC, PFE Pfizer Holdings 1 LLC, PFE Wyeth Holdings LLC, PFE Wyeth-Ayerst (Asia) LLC, PHILCO Holdings S.à r.l., PHIVCO Corp., PHIVCO Holdco S.à r.l., PHIVCO Luxembourg S.à r.l., PN Mexico LLC, PT. Pfizer Parke Davis, Parke Davis & Company LLC, Parke Davis Limited, Parke Davis Productos Farmaceuticos Lda, Parke-Davis Manufacturing Corp., Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Limited, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Africa & Middle East for Pharmaceuticals Veterinarian Products & Chemicals S.A.E., Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Asia Pacific Pte Ltd., Pfizer Atlantic Holdings S.a.r.l., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty. Ltd., Pfizer Australia Pty Limited, Pfizer B.V., Pfizer BH D.o.o., Pfizer Baltic Holdings B.V., Pfizer Biofarmacêutica Sociedade Unipessoal Lda, Pfizer Biologics (Hangzhou) Co. Ltd, Pfizer Biologics Ireland Holdings Limited, Pfizer Biotech Corporation, Pfizer Bolivia S.A., Pfizer Canada Inc., Pfizer CentreSource Asia Pacific Pte. Ltd., Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Commercial Holdings Coöperatief U.A., Pfizer Commercial Holdings TRAE Kft., Pfizer Commercial TRAE Trading Kft., Pfizer Consumer Healthcare AB, Pfizer Consumer Healthcare GmbH, Pfizer Consumer Healthcare Ltd., Pfizer Consumer Manufacturing Italy S.r.l., Pfizer Corporation, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer Domestic Ventures Limited, Pfizer Dominicana S.R.L, Pfizer ESP Pty Ltd, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Egypt S.A.E., Pfizer Enterprise Holdings B.V., Pfizer Enterprises LLC, Pfizer Enterprises SARL, Pfizer Europe Finance B.V., Pfizer Export B.V., Pfizer Export Company, Pfizer Export Holding Company B.V, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer Financial Services N.V./S.A., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer GEP S.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Group Luxembourg Sarl, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer HK Service Company Limited, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holding Ventures, Pfizer Holdings Corporation, Pfizer Holdings Europe Unlimited Company, Pfizer Holdings G.K., Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Holdings North America SARL, Pfizer Hungary Holdings TRAE Kft., Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer Innovative Supply Point International BVBA, Pfizer International LLC, Pfizer International Markets Coöperatief U.A., Pfizer International Operations, Pfizer International S. de R.L., Pfizer International Trading (Shanghai) Limited, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Investment Holdings S.a.r.l., Pfizer Ireland Investments Limited, Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Italy Group Holding S.r.l., Pfizer Japan Inc., Pfizer LLC, Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Laboratories PFE (Pty) Ltd, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limitada, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medical Technology Group (Belgium) N.V., Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Luxco SARL, Pfizer Mexico S.A. de C.V., Pfizer Middle East for Pharmaceuticals Animal Health and Chemicals S.A.E., Pfizer New Zealand Limited, Pfizer Norge AS, Pfizer North American Holdings Inc., Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE ApS, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE Australia Holding B.V., Pfizer PFE Australia Pty Ltd, Pfizer PFE B.V., Pfizer PFE Baltic Holdings B.V., Pfizer PFE Belgium SPRL, Pfizer PFE Brazil Holding S.à r.l., Pfizer PFE CIA. Ltda., Pfizer PFE Chile Holding LLC, Pfizer PFE Colombia Holding Corp., Pfizer PFE Colombia S.A.S, Pfizer PFE Commercial Holdings LLC, Pfizer PFE Croatia Holding B.V., Pfizer PFE Eastern Investments B.V., Pfizer PFE Finland Oy, Pfizer PFE France, Pfizer PFE Global Holdings B.V., Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V., Pfizer PFE Italy Holdco 2 S.à r.l., Pfizer PFE Italy Holdco S.à r.l., Pfizer PFE Korlátolt Felelősségű Társaság, Pfizer PFE Limited, Pfizer PFE Luxembourg S.à r.l., Pfizer PFE Mexico Holding 3 LLC, Pfizer PFE Netherlands Holding 1 C.V., Pfizer PFE New Zealand, Pfizer PFE New Zealand Holding B.V., Pfizer PFE Norway Holding S.à r.l., Pfizer PFE PILSA Holdco S.à r.l., Pfizer PFE Peru Holding LLC, Pfizer PFE Peru S.R.L., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Private Limited, Pfizer PFE S.R.L, Pfizer PFE Service Company Holding Coöperatief U.A., Pfizer PFE Singapore Holding B.V., Pfizer PFE Singapore Pte. Ltd., Pfizer PFE Spain B.V., Pfizer PFE Spain Holding S.L., Pfizer PFE Sweden Holding 2 S.á.r.l., Pfizer PFE Sweden Holding S.á.r.l., Pfizer PFE Switzerland GmbH, Pfizer PFE Turkey Holding 1 B.V., Pfizer PFE Turkey Holding 2 B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE US Holdings 1 LLC, Pfizer PFE US Holdings 2 LLC, Pfizer PFE US Holdings 3 LLC, Pfizer PFE US Holdings 4 LLC, Pfizer PFE US Holdings 5 LLC, Pfizer PFE spol. s r.o., Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Parke Davis (Thailand) Ltd., Pfizer Parke Davis Inc., Pfizer Parke Davis Sdn. Bhd., Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals B.V., Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals LLC, Pfizer Pharmaceuticals Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. (Belgium), Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SRB d.o.o., Pfizer Saidal Manufacturing, Pfizer Santé Familiale, Pfizer Saudi Limited, Pfizer Seiyaku K.K., Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Services 1, Pfizer Services LLC, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Singapore Trading Pte. Ltd., Pfizer Spain Holdings Coöperatief U.A., Pfizer Specialties Limited, Pfizer Strategic Investment Holdings LLC, Pfizer Sweden Partnership KB, Pfizer TRAE Holdings Kft., Pfizer Trading Polska sp.z.o.o., Pfizer Transactions Ireland Unlimited Company, Pfizer Transactions LLC, Pfizer Transactions Luxembourg SARL, Pfizer Transport LLC, Pfizer Ukraine LLC, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Venture Investments LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company Inc., Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia & Upjohn S.A. de C.V., Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Holding AB, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, Pharmacia Nostrum S.A., Pharmacia South Africa (Pty) Ltd, PowderJect Research Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig Produtos Farmaceuticos Lda., Roerig S.A., Sao Cristovao Participacoes Ltda., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Site Realty Inc., Solinor LLC, Sugen LLC, Tabor LLC, The Pfizer Incubator LLC, Therachon, Thiakis Limited, Treerly Health Co. Ltd, US Oral Pharmaceuticals Pty Ltd, Upjohn Laboratorios Lda., Vesterålens Naturprodukter A/S, Vesterålens Naturprodukter AB, Vesterålens Naturprodukter AS, Vesterålens Naturprodukter OY, Vicuron Holdings LLC, Vinci Farma S.A., W-L LLC, Warner Lambert, Warner Lambert Ilac Sanayi ve Ticaret Limited Sirketi, Warner Lambert del Uruguay S.A., Warner-Lambert (Thailand) Limited, Warner-Lambert Company AG, Warner-Lambert Company LLC, Warner-Lambert Guatemala Sociedad Anonima, Warner-Lambert S.A., Whitehall International Inc., Whitehall Laboratories Inc., Wyeth (Thailand) Ltd., Wyeth AB, Wyeth Australia Pty. Limited, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Canada ULC, Wyeth Consumer Healthcare LLC, Wyeth Europa Limited, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth KFT., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Lederle Vaccines S.A., Wyeth Pakistan Limited, Wyeth Pharmaceutical Co. Ltd., Wyeth Pharmaceuticals Company, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Pharmaceuticals Limited, Wyeth Puerto Rico Inc., Wyeth S.A.S, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth Whitehall SARL, Wyeth-Ayerst (Asia) Limited, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More

When was Pfizer founded?

Pfizer was founded in 1849.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.